Item no. |
230-30216-500 |
Manufacturer |
Raybiotech
|
Amount |
500 ug |
Category |
|
Type |
Proteins Recombinant |
Format |
Lyophilized powder |
Applications |
WB, IP, ELISA, Dot |
Specific against |
Human |
Conjugate/Tag |
His |
Purity |
>95% - SDS-PAGE under reducing conditions and visualized by Coomassie blue staining |
ECLASS 10.1 |
32160409 |
ECLASS 11.0 |
32160409 |
UNSPSC |
12352202 |
Available |
|
Application Information |
Functional Assay, Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc. |
Storage/Stability |
Upon arrival, the lyophilized protein may be stored for 2 weeks at 4°C. For long term storage, it is recommended to store desiccated below -20 °C in a manual defrost freezer. Following reconstitution, the protein may be stored for 2 weeks under sterile conditions at -20 °C. For long term storage, it is recommended to make appropriate aliquots and store at -80 °C. Avoid repeated freeze-thaw cycles. |
Formulation |
Lyophilized from a 0.2 um filtered solution in PBS (pH 7.4) |
Expressed Region |
Lys26-Asn339 |
Expression System |
Human embryonic kidney 293 (HEK293) cells |
Purification |
His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC) |
Concentration (lot specific) |
Determined by BCA protein assay |
Reconstitution |
Briefly spin the vial and bring the contents to the bottom prior to opening. It is recommended to reconstitute at 0.5 - 1.0 mg/mL with sterile deionized water. |
Endotoxin Level |
<0.5 EU per ug of the protein as determined by the LAL method |
Conjugation/Tag Notes |
C-terminal His-tag |
Molecular Weight (kDa) |
Recombinant protein product has a calculated molecular mass of 35 kDa. Due to the abundant glycosylation, it migrates as approximately 45 kDa major protein band in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions. See deglycosylation analysis image below. |
SDS-PAGE Image |
Figure 1. Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated. Lane 1: protein standard ladder (kDa).Lane 2: untreated protein.Lane 3: treated protein with deglycosylation enzymes under native conditions.Lane 4: treated protein with deglycosylation enzymes under denature conditions. |
Shipping |
Ice packs |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.